Evidence map›Paper›PMID 18026149›Full record

Trial reportBone marrow transplantation2008

High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial.

C Papadimitriou, U Dafni, A Anagnostopoulos, G Vlachos, Z Voulgaris, A Rodolakis, G Aravantinos, A Bamias, G Bozas, E Kiosses and 3 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05401162 (Conventional Dose Chemotherapy for Ovarian Cancer Supported by Autologous Haematopoietic Stem Cell Transfusion), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05401162 narecruitingnot on this mapstarted 2022, after this paper: background citation

Conventional Dose Chemotherapy for Ovarian Cancer Supported by Autologous Haematopoietic Stem Cell Transfusion

TypeinterventionalSponsorChongqing University Cancer HospitalRan2022 to 2029Enrolled40ConditionsOvarian CancerArmsAutologous blood transfusion with haematopoietic stem cells
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2015
    Article
  4. Are there candidates for high-dose chemotherapy in ovarian carcinoma?Journal of experimental & clinical cancer research : CR · 2012
    Article
  5. Stem cells in clinical practice: applications and warnings.Journal of experimental & clinical cancer research : CR · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

C PapadimitriouDepartment of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece. chr_papadim@yahoo.gr
U Dafni
A Anagnostopoulos
G Vlachos
Z Voulgaris
A Rodolakis
G Aravantinos
A Bamias
G Bozas
E Kiosses
G M Gourgoulis
E Efstathiou
M A Dimopoulos
Alexandra Hospital · GRNational and Kapodistrian University of Athens · GRHospital Agioi Anargyroi · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of high-dose chemotherapy (HDCT) in epithelial ovarian cancer (EOC) remains controversial. This study was initiated to compare the efficacy and tolerability of HDCT as a consolidation approach in women with chemosensitive advanced EOC (FIGO stages IIC-IV). Patients who had achieved their first clinical complete remission after six cycles of conventional paclitaxel and carboplatin combination chemotherapy were randomly assigned to receive or not high-dose melphalan. The primary objective was to compare time to disease progression (TTP). A total of 80 patients were enrolled onto the trial. Patients who were randomized to receive HDCT were initially treated with cyclophosphamide 4 g/m(2) for PBPC mobilization. HDCT consisted of melphalan 200 mg/m(2). Of the 37 patients who were allocated to HDCT, 11 (29.7%) did not receive melphalan either due to patient refusal (n=5) or due to failure of PBPC mobilization (n=6). In an intent-to-treat analysis, there were no significant differences between the two arms in TTP (P=0.059) as well as in overall survival (OS) (P=0.38).

Indexed as

Hematopoietic Stem Cell TransplantationAdjuvants, ImmunologicAdultAgedAntineoplastic Agents, AlkylatingBlood Transfusion, AutologousCombined Modality TherapyCyclophosphamideDisease ProgressionFemaleGranulocyte Colony-Stimulating FactorHumansLenograstimMelphalanMiddle AgedOvarian NeoplasmsAdjuvants, ImmunologicAntineoplastic Agents, AlkylatingCyclophosphamideGranulocyte Colony-Stimulating FactorLenograstimMelphalanRecombinant Proteins

Identifiers

PMID18026149
OpenAlexW2010532934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.